1. SYNOPSIS



The Company

Theraptosis S.A. , a biotechnology company, was founded in April 2001.

Theraptosis designs and develops various drugs that act on key apoptosis regulators to fight diseases associated with lack or excess of apoptosis including cancer and neurodegenerative diseases. The Company's key assets include a dual technology platform (CytoTrust™ and MitoTrust™) for screening and targeting purposes and a pipeline of products in the areas of CNS and oncology. Theraptosis’ discovery engines integrate mitochondria, and apoptosis expertise, and has developed pre-clinical animal models.

Theraptosis assets today include:

•  An original technology platform with proven usefulness in: drug discovery, target identification, screening and development
•  A new therapeutic approach of ischaemic phenomena with an anti-apoptotic product which is expected to go to clinic in 2008
•  Lead compounds in oncology , based on specific screening on mitochondria
•  An actively managed portfolio of 15 patent series.

 

 

Profile

Mission :  Drug discovery and developpement
Strategy :  Apoptosis control
Fields :  Central nervous system
Oncology
Founded :  April 2001
Spin-off of the Pasteur Institute
Financing :  10.65 million euro
Grants & Awards:  3.35 million euro
Total:  14 million euro
Institutional Investors: 

Auriga Partners
Seventure (Natexis Private Equity)
Edmond de Rothschild Investment Partners S.A.S. (EdRIP)
CDC entreprises (FCJE)

Blue Medical Investment

Employees :  20
Industrial Property :  15 patent families

>> 2. Organization

 

français site map
contact us links






Theraptosis S.A. - Biocitech Technology Park - Lavoisier building
102 Avenue Gaston Roussel, F-93235 Romainville Cedex, France
Phone: +33 1 57 14 08 08 - Fax : +33 1 57 42 19 42
email: info@theraptosis.com